Best of 2016
2016 has been an exciting year of for JCC. The 10th volume was published, the journal's Impact Factor continued to rise to 6.585, and there were more article downloads than ever before.
Explore our free to access selection of key papers published in 2016 including the most cited, most downloaded and highest Altmetric scoring articles.
Thank you to all of the authors and reviewers that have contributed to the journal's success.
Highly cited articles
Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort
Krisztina B. Gecse, Barbara D. Lovász, Klaudia Farkas, et al.
Donor Species Richness Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel Disease
Severine Vermeire, Marie Joossens, Kristin Verbeke, et al.
Impact of New Treatments on Hospitalisation, Surgery, Infection, and Mortality in IBD: a Focus Paper by the Epidemiology Committee of ECCO
Vito Annese, Dana Duricova, Corinne Gower-Rousseau, et al.
Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations
J. Sieczkowska, D. Jarzębicka, A. Banaszkiewicz, et al.
Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease
Alon D. Levin, Manon E. Wildenberg, and Gijs R. van den Brink
Most downloaded articles
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
A. Dignass, G. Van Assche, J.O. Lindsay, et al.
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management
Axel Dignass, James O. Lindsay, Andreas Sturm, et al.
The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease
Marcus Harbord, Vito Annese, Stephan R. Vavricka, et al.
European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies
Vito Annese, Laurent Beaugerie, Laurence Egan, et al.
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis
Axel Dignass, Rami Eliakim, Fernando Magro, et al.
Top Altmetric scoring
Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Abdominal Operations for Inflammatory Bowel Disease
Amy L. Lightner, Laura E. Raffals, Kellie L. Mathis, et al.
Long-term Efficacy of Vedolizumab for Ulcerative Colitis
Edward V. Loftus, Jr, Jean-Frédéric Colombel, Brian G. Feagan, et al.
Long-term Efficacy of Vedolizumab for Crohn’s Disease
Severine Vermeire, Edward V. Loftus, Jr, Jean-Frédéric Colombel, et al.
Designer Thiopurine-analogues for Optimised Immunosuppression in Inflammatory Bowel Diseases
Imke Atreya, Alexandra Diall, Radovan Dvorsky, et al.
Similar Depletion of Protective Faecalibacterium prausnitzii in Psoriasis and Inflammatory Bowel Disease, but not in Hidradenitis Suppurativa
Hester Eppinga, Christa J. Sperna Weiland, H. Bing Thio, et al.